Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherap. LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 10.125p 9.75p 10.50p 10.125p 10.125p 10.125p 66,896 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.7 -1.1 - 12.02

Skinbiotherap. (SBTX) Latest News

More Skinbiotherap. News
Skinbiotherap. Takeover Rumours

Skinbiotherap. (SBTX) Share Charts

1 Year Skinbiotherap. Chart

1 Year Skinbiotherap. Chart

1 Month Skinbiotherap. Chart

1 Month Skinbiotherap. Chart

Intraday Skinbiotherap. Chart

Intraday Skinbiotherap. Chart

Skinbiotherap. (SBTX) Discussions and Chat

Skinbiotherap. (SBTX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-20 15:34:2610.0050,0005,000.00O
2017-11-20 14:32:3110.004,155415.50O
2017-11-20 13:28:4210.472,330243.95O
2017-11-20 09:43:1910.479,456990.04O
2017-11-20 08:01:0610.4795599.99O
View all Skinbiotherap. trades in real-time

Skinbiotherap. (SBTX) Top Chat Posts

DateSubject
20/11/2017
08:20
Skinbiotherap. Daily Update: Skinbiotherap. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherap. was 10.13p.
Skinbiotherap. has a 4 week average price of 9.75p and a 12 week average price of 9.38p.
The 1 year high share price is 17.75p while the 1 year low share price is currently 8p.
There are currently 118,708,494 shares in issue and the average daily traded volume is 239,589 shares. The market capitalisation of Skinbiotherap. is £12,019,235.02.
16/11/2017
16:26
elrico: Bob - Last word on the subject of SBTX share...well, not my words, but SOH from an email exchange on this and other topics. There was also a phone call where in-specie divi was used, which has been repeated by SOH. All I would ask of you, Bob, in your opinion how do you expect OPTI to "release value BACK to shareholders?" Thanks Elric, Our emails crossed over as I sent a quick response last night whilst travelling. I always value your insight and agree with the issues. Just to help in terms of guidance:- 1. We have always made clear our approach to SBTX which was outlined in my presentations at the Investor Show and recent investor meeting a. Our focus is on building value in SBTX b. Our aim is release value back to shareholders without unduly impacting on both SBTX and OPTI value c. We are working on the best way of achieving this with our advisors d. We hope to have the details worked out in the near future and announced so shareholders will see how they can benefit
04/10/2017
16:38
shazbo: elrico, just picking your brain here on timing. I'm no trader, don't have the skills or the time but equally don't see the point in putting money into a stock that potentially won't see any revenue for 2 years. Wouldn't it be better to put your money into something that you at least think (easier said than done I know) will make some profit then release what you've saved/made to buy in here in 18/24 months time? Or do you see some (non revenue)news on the horizon that will give a decent share price uplift within that two years? I know we shouldn't always compare to Opti BUT I've built up a decent position there through believing the share price would race ahead much quicker than it has (my misjudgement) but if you'd said to me two years ago you'll make no money on this would I still have done it? Probably not. Hindsight is a wonderful thing and I'm in Opti for the long term and luckily don't need to take anything out for the foreseeable future. But it seems like you're saying here you are fairly confident we won't see any revenue for a while so why the rush to be in so early with money that won't be working hard for you in that time? Each to their own and all that, but just interested in your thinking if you don't mind sharing. Cheers.
02/9/2017
09:07
f3rdinand: I think we are potentially due an update before the financial results in October! From what I gather work is ongoing at the moment with a third party to produce the base lysate material on a large scale and ensure the produced material is within the required range of toxicology! If this is successful it can then move to human testing next year! This is when I'd expect to see the real share price appreciation.
25/8/2017
13:44
rafboy: We don't yet know how the SBTX share divest will work out. So if I hold 50,000 OPTI I have no idea how many SBTX shares I will get at the moment. How did you work it out owenmo?
23/8/2017
08:52
elrico: I previously suggested SBTX & OPTI share price would be linked, I know many didn't agree. So far I have been proved correct. The disconnect will occur once both companies demerg interest and build their own markets.
30/6/2017
16:46
parob: Well I've been taking advantage and have been loading up whilst we're down here. Once the remaining placing shares are flipped - and there can't be many left - I agree this will fly, especially with news! As kipper1960 mentioned earlier on the OPTI thread there's always the possibility OPTI are waiting for the SBTX price to rise before announcing news on the distribution of shares to OPTI holders. We might not have too long to wait with another 700K offloaded today.I wonder if any of the buying today is on the back of the investor meeting - decent volume, highest in a month and we're up almost 4%. Here's hoping for a big blue week next week.
06/6/2017
18:04
onedayrodders: Ageed elrico ... but a little more credability to the microbiome science and a surging OPTI share price should have some impact here. IMHO
Skinbiotherap. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171121 02:35:30